December 27, 2024 08:45 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
I have lost a mentor and guide: Rahul Gandhi writes on Manmohan Singh's demise | Manmohan Singh left strong imprint on our economic policy over years: PM Modi | A rare leader who spoke softly but achieved monumental strides: Gautam Adani mourns Manmohan Singh's death | Instagram influencer and freelance RJ Simran Singh dies by suicide in Gurugram | Anna University sexual assault case: Accused is a DMK worker, claims BJP's Annamalai | Celebrities too responsible for crowd control: Telangana CM Revanth Reddy to Telugu filmdom amid Pushpa 2 stampede row | Boat capsizes off Calangute Beach in Goa; 1 killed, 20 rescued | Canada announces change to immigration system, likely to impact Indians seeking permanent residence | Azerbaijan Airlines tragedy: 32 passengers rescued, flight attempted several emergency landing before crashing | Man sets himself on fire near Parliament building; locals, police rush him to hospital
Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India

Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India

May 12, 2020, at 07:55 pm

MUMBAI/PRNewswire -- Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India's drug regulator DCGI in late April. Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India. Favipiravir is a generic version of Avigan® of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government and private hospitals in India are being enrolled for the study. Glenmark estimates study completion by July/August 2020.